10 Best German Stocks To Buy Now

3. InflaRx N.V. (NASDAQ:IFRX)

Upside potential as of November 15: 233.33%

InflaRx N.V. (NASDAQ:IFRX) is a clinical-stage biopharmaceutical company that uses patented anti-C5a/C5aR technology to identify and develop first-in-class, powerful, and selective inhibitors of the complement activation factor C5a and its receptor, C5aR. The development of several autoimmune and other inflammatory diseases is influenced by the inflammatory mediator C5a.

Vilobelimab, its main product candidate, is a brand-new intravenously administered, first-in-class anti-C5a monoclonal antibody that binds to free C5a specifically and has shown tolerability and disease-modifying clinical activity in a variety of clinical settings.

InflaRx N.V. (NASDAQ:IFRX) recently disclosed its third-quarter 2024 financial results, which demonstrated both continued financial stability and noteworthy clinical trial milestones. The accomplishment of patient recruitment milestones in InflaRx’s Phase 3 Vilobelimab study for pyoderma gangrenosum and the ongoing advancement of their therapeutic pipeline, which is expected to begin a Phase 2a trial for INF904 by the end of 2024, are two of the report’s main highlights. For the first nine months of 2024, InflaRx recorded a net loss of €41.0 million ($43.4 million), which was mostly caused by a decline in other revenue from government grants that terminated in mid-2023. Despite this, the company has €62.0 million ($65.6 million) in cash and marketable securities, which should sustain operations into 2026.

Looking ahead, InflaRx N.V. (NASDAQ:IFRX) is still committed to developing its clinical programs and investigating new market prospects, and it has high hopes for reaching significant milestones in 2025. Positive developments for InflaRx, such as CHMP’s recommendation for Gohibic’s approval for severe COVID-19 ARDS, support the company’s potential for expansion. Despite regulatory obstacles, its commercial outlook is further strengthened by the impending European ruling and continued FDA discussions.